JP7113619B2 - リポソーマルイリノテカンによる乳がんの治療 - Google Patents

リポソーマルイリノテカンによる乳がんの治療 Download PDF

Info

Publication number
JP7113619B2
JP7113619B2 JP2017530656A JP2017530656A JP7113619B2 JP 7113619 B2 JP7113619 B2 JP 7113619B2 JP 2017530656 A JP2017530656 A JP 2017530656A JP 2017530656 A JP2017530656 A JP 2017530656A JP 7113619 B2 JP7113619 B2 JP 7113619B2
Authority
JP
Japan
Prior art keywords
breast cancer
irinotecan
composition
patient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017530656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537124A5 (https=
JP2017537124A (ja
Inventor
エリエル ベイバー，
ジョナサン バジル フィッツジェラルド，
ジェヨン キム，
スティーブン クリンツ，
Original Assignee
イプセン バイオファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イプセン バイオファーム リミティド filed Critical イプセン バイオファーム リミティド
Publication of JP2017537124A publication Critical patent/JP2017537124A/ja
Publication of JP2017537124A5 publication Critical patent/JP2017537124A5/ja
Application granted granted Critical
Publication of JP7113619B2 publication Critical patent/JP7113619B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017530656A 2014-12-09 2015-12-08 リポソーマルイリノテカンによる乳がんの治療 Expired - Fee Related JP7113619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089685P 2014-12-09 2014-12-09
US62/089,685 2014-12-09
PCT/US2015/064491 WO2016094402A1 (en) 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020022400A Division JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療

Publications (3)

Publication Number Publication Date
JP2017537124A JP2017537124A (ja) 2017-12-14
JP2017537124A5 JP2017537124A5 (https=) 2019-01-24
JP7113619B2 true JP7113619B2 (ja) 2022-08-05

Family

ID=54979964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017530656A Expired - Fee Related JP7113619B2 (ja) 2014-12-09 2015-12-08 リポソーマルイリノテカンによる乳がんの治療
JP2020022400A Withdrawn JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療
JP2022045463A Pending JP2022079545A (ja) 2014-12-09 2022-03-22 リポソーマルイリノテカンによる乳がんの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020022400A Withdrawn JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療
JP2022045463A Pending JP2022079545A (ja) 2014-12-09 2022-03-22 リポソーマルイリノテカンによる乳がんの治療

Country Status (6)

Country Link
US (2) US20160346272A1 (https=)
EP (1) EP3229802A1 (https=)
JP (3) JP7113619B2 (https=)
AU (1) AU2015360761B2 (https=)
HK (1) HK1245133A1 (https=)
WO (1) WO2016094402A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) * 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
AU2019317986A1 (en) * 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536247A (ja) 2004-05-03 2007-12-13 ヘルメス バイオサイエンシズ インコーポレーティッド 薬物送達に有用なリポソーム
JP2013531069A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法
WO2013188586A1 (en) 2012-06-13 2013-12-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
EP3337467B1 (en) * 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) * 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
MX382522B (es) * 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536247A (ja) 2004-05-03 2007-12-13 ヘルメス バイオサイエンシズ インコーポレーティッド 薬物送達に有用なリポソーム
JP2013531069A (ja) 2010-07-19 2013-08-01 バイパー サイエンシズ，インコーポレイティド ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法
WO2013188586A1 (en) 2012-06-13 2013-12-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ＡＮＴＩＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ，２００５年，Ｖｏｌ ２５，ｐｐ．１５３１－１５３７
Ｂｒｅａｓｔ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ ａｎｄ Ｔｒｅａｔｍｅｎｔ，２０２０年（ＵＲＬ，ｈｔｔｐｓ：／／ｄｏｉ．ｏｒｇ．／１０．１００７／ｓ１０５４９－０２０－０５９９５－７，ｐｕｂｌｉｓｈｅｄ ｏｎｌｉｎｅ １７ Ｎｏｖ．２０２０）
Ｂｒｅａｓｔ Ｃａｎｃｅｒ，２０１３年，Ｖｏｌ．２０，Ｎｏ．２，ｐｐ．１３１－１３６（ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１００７／ｓ１２２８２－０１１－０３１６－ｚ）
ＣＡＮＣＥＲ ＣＨＥＭＯＴＨＥＲＡＰＹ ＡＮＤ ＰＨＡＲＭＡＣＯＬＯＧＹ，２０１２年，Ｖｏｌ．７０，Ｎｏ．５，ｐｐ．６９９－７０５（ＵＲＬ，ｈｔｔｐ：／／ｄｘ．ｄｏｉ．ｏｒｇ／１０．１００７／ｓ００２８０－０１２－１９６０－５）
Ｃｈｅｎ ｅｔ ａｌ．，Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｏｎｃｏｌｏｇｙ，２００８年，Ｖｏｌ．２６，Ｎｏ．１５＿ｓｕｐｐｌ（ｄｏｉ：１０．１２００／ｊｃｏ．２００８．２６．１５＿ｓｕｐｐｌ．２５６５）
Ｎａｎｏｍｅｄｉｃｉｎｅ （Ｌｏｎｄ），２０１４年７月，Ｖｏｌ．９，Ｎｏ．１４，ｐｐ．２０９９－２１０８

Also Published As

Publication number Publication date
JP2022079545A (ja) 2022-05-26
HK1245133A1 (zh) 2018-08-24
US20200360367A1 (en) 2020-11-19
EP3229802A1 (en) 2017-10-18
US20160346272A1 (en) 2016-12-01
JP2020073601A (ja) 2020-05-14
WO2016094402A1 (en) 2016-06-16
AU2015360761B2 (en) 2021-05-20
AU2015360761A1 (en) 2017-06-15
JP2017537124A (ja) 2017-12-14

Similar Documents

Publication Publication Date Title
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
TWI646959B (zh) 癌症之治療方法
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
US10744110B2 (en) Methods of treating lung cancer
CN105792845A (zh) 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
TW201141472A (en) Method to treat small cell lung cancer
US20020151508A1 (en) Methods for treating proliferative diseases
US20190142822A1 (en) Treatment of Breast Cancer with Liposomal Irinotecan
Fattoruso et al. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан
TW202513098A (zh) 治療癌症之方法
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201120

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201204

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210105

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210326

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210330

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211223

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220322

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220616

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220708

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220726

R150 Certificate of patent or registration of utility model

Ref document number: 7113619

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees